Solid dosage formulations of an orexin receptor antagonist
View Patent ↗The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant. The concentration-enhancing polymer is a polymer that forms an amorphous dispersion with suvorexant, that is insoluble or almost completely insoluble in water by (a) dissolving the suvorexant or (b) interacting with the suvorexant in such a way that the suvorexant does not form crystals or crystalline domains in the polymer. A concentration-enhancing polymer is water soluble or readily disperse in water, so that when the polymer is placed in water or an aqueous environment (e.g. fluids in the gastrointestinal (GI) tract or simulated GI fluids), the solubility and/or bioavailability of suvorexant is increased over the solubility or bioavailability in the absence of the polymer.
1. A pharmaceutical composition comprising:
suvorexant in an amorphous form; and
copovidone;
wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone.
2. The pharmaceutical composition of claim 1 , wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
3. The pharmaceutical composition of claim 1 , wherein the suvorexant is present in a form that contains at least 95 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
4. The pharmaceutical composition of claim 1 , wherein the suvorexant is present in a form that contains at least 98 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
5. The pharmaceutical composition of claim 1 , wherein the suvorexant is present in a form that contains at least 99 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition additionally comprises lactose.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition additionally comprises microcrystalline cellulose.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition additionally comprises croscarmellose sodium.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition additionally comprises magnesium stearate.
10. A pharmaceutical composition comprising:
suvorexant in an amorphous form;
copovidone;
lactose monohydrate;
microcrystalline cellulose;
croscarmellose sodium; and
magnesium stearate;
wherein the pharmaceutical composition is prepared by a process comprising hot melt extrusion of a mixture comprising suvorexant and copovidone.
11. The pharmaceutical composition of claim 10 , wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
12. The pharmaceutical composition of claim 10 , wherein the suvorexant is present in a form that contains at least 95 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
13. The pharmaceutical composition of claim 10 , wherein the suvorexant is present in a form that contains at least 98 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
14. The pharmaceutical composition of claim 10 , wherein the suvorexant is present in a form that contains at least 99 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.
15. The pharmaceutical composition of claim 11 , which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.
16. The pharmaceutical composition of claim 12 , which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.
17. The pharmaceutical composition of claim 13 , which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.
18. The pharmaceutical composition of claim 14 , which comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant.